SZShengjie Zhang

Shengjie Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shengjie Zhang has a total of 46 co-authors. Here are the top co-authors by number of shared publications:

  • Yi-Ping Wang

    Precision Research Center for Refractory Diseases, Institute for Clinical Research, Shanghai Jiao Tong University Pioneer Research Institute for Molecular and Cell Therapies, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    4 shared publications
  • Jingyi Wang

    Precision Research Center for Refractory Diseases, Shanghai Jiao Tong University Pioneer Research Institute for Molecular and Cell Therapies, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    3 shared publications
  • Sijun Sun

    Precision Research Center for Refractory Diseases, Shanghai Jiao Tong University Pioneer Research Institute for Molecular and Cell Therapies, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    3 shared publications
  • Chengmei Xie

    Precision Research Center for Refractory Diseases, Institute for Clinical Research, Shanghai Key Laboratory of Pancreatic Disease, Shanghai General Hospital Shanghai Jiao Tong University School of Medicine China

    2 shared publications
  • Haiyan Wang

    Department of Ophthalmology, Shanghai General Hospital Shanghai Jiao Tong University School of Medicine China

    2 shared publications
  • Tianshi Wang

    Department of Nephrology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China

    2 shared publications

Latest Publications

  • Open Access

    Exploring mitochondrial central dogma in cancer from a metabolic perspective

    by Shengjie Zhang, Beisi Han, Lu Chen, Lingchao Chen, Tianshi Wang, Miao Lin, Jun Liu, Yiping Wang

    Mitochondria are metabolic hubs that house their own genomes (mitochondrial DNA [mtDNA]), which encode components of the oxidative phosphorylation (OXPHOS) machinery. The mitochondrial central dogma not only governs compartmentalised metabolism but also intensively intertwines with multiple biological processes, and its dysregulation is a hallmark of cancer and metabolic diseases. In this review, we highlight recent advances in mitochondrial biogenesis from a metabolic perspective, with a particular emphasis on cancer. Metabolites act as donors for diverse chemical modifications, which have been systematically identified on mtDNA, rRNA, and tRNA. Besides, post-translational modifications of proteins involved in mtDNA replication, transcription, and translation has been revealed to connect metabolic signals with mitochondrial biogenesis. A comprehensive landscape of the mitochondrial central dogma has deepened our understanding of how mitochondria coordinate OXPHOS with other organelle-specific processes to obtain a flexible metabolic network, which potentiates tumor growth. Notably, non-canonical products and biological functions of the mitochondrial central dogma further reshape our concepts of cancer initiation and progression. Given that dysregulated mitochondrial biogenesis is found in multiple human disorders, including cancer, targeting this pathway offers new therapeutic opportunities. Genome-wide studies and drug screens have identified metabolic nodes and small molecules with potential to correct mitochondrial dysfunction in cancer, while emerging tools such as mtDNA editing enable precise intervention. Despite a maturing picture of mitochondrial biogenesis, many hidden players and functions remain to be uncovered to fully decipher mitochondrial biology in cancer.

  • Open Access

    BCAT1 Activation Reprograms Branched-Chain Amino Acid Metabolism and Epigenetically Promotes Inflammation in Diabetic Retinopathy

    by Jingyi Wang, Zihan Yin, Jingxiao Yang, Sijun Sun, Xiaofang Tang, Shengjie Zhang, Yi-Ping Wang, Haiyan Wang

    To investigate how branched-chain amino acid (BCAA) metabolism is remodeled and to determine its contribution to diabetic retinopathy progression. We analyzed Bcat1 and Bcat2 expression in the retina using single-cell sequencing data and immunofluorescence. Bcat1-mediated remodeling of BCAA metabolism was assessed via targeted metabolomics in Müller cells. We performed chromatin immunoprecipitation (ChIP) to examine histone methylation at inflammatory gene promoters. Additionally, we utilized RNA sequencing and kinase screening assays to delineate phosphorylation regulation of Bcat1 activity. In vivo, we established diabetic mouse models and treated them with Bcat1-specific inhibitor to evaluate retinal inflammation and vascular leakage. Bcat1 was predominantly expressed in Müller cells and exhibited increased activity under diabetic conditions, leading to a remodeling of BCAA catabolism and upregulation of inflammatory genes (interleukin 6 [Il6] and tumor necrosis factor-α [Tnf-α]). Bcat1 activity was negatively regulated by polo-like kinase 4 (Plk4)-mediated phosphorylation at threonine 333. In high glucose-treated Müller cells, elevated Bcat1 activity reduced α-ketoglutarate (α-KG), a critical substrate for histone demethylation reactions, resulting in higher histone H3 lysine 4 trimethylation (H3K4me3) levels at inflammatory gene promoters, and further boosted retinal inflammation. Treatment with chemical Bcat1 inhibitors (BAY-069 and ERG240) significantly reduced inflammatory gene expression and vascular leakage in diabetic retinas in vivo. Bcat1 activation mediates BCAA metabolism remodeling in Müller cells and epigenetically induces retinal inflammation, which offers a potential therapeutic target for diabetic retinopathy. Diabetes and diabetic retinopathy are potentially driven not only by hyperglycemia but also by dysregulated amino acid metabolism.


  • Open Access

    WBSCR16 is essential for mitochondrial 16S rRNA processing in mammals

    by Shengjie Zhang, Zi Dong, Yang Feng, Wei Guo, Chen Zhang, Yifan Shi, Zhiyun Zhao, Jiqiu Wang, Guang Ning, Guorui Huang

    Mitochondrial rRNAs play important roles in regulating mtDNA-encoded gene expression and energy metabolism subsequently. However, the proteins that regulate mitochondrial 16S rRNA processing remain poorly understood. Herein, we generated adipose-specific Wbscr16-/-mice and cells, both of which exhibited dramatic mitochondrial changes. Subsequently, WBSCR16 was identified as a 16S rRNA-binding protein essential for the cleavage of 16S rRNA-mt-tRNALeu, facilitating 16S rRNA processing and mitochondrial ribosome assembly. Additionally, WBSCR16 recruited RNase P subunit MRPP3 to nascent 16S rRNA and assisted in this specific cleavage. Furthermore, evidence showed that adipose-specific Wbscr16 ablation promotes energy wasting via lipid preference in brown adipose tissue, leading to excess energy expenditure and resistance to obesity. In contrast, overexpression of WBSCR16 upregulated 16S rRNA processing and induced a preference for glucose utilization in both transgenic mouse models and cultured cells. These findings suggest that WBSCR16 plays essential roles in mitochondrial 16S rRNA processing in mammals, and is the key mitochondrial protein to balance glucose and lipid metabolism.


  • THAP3 recruits SMYD3 to OXPHOS genes and epigenetically promotes mitochondrial respiration in hepatocellular carcinoma

    by Zi‐Hao Wang, Jingyi Wang, Fuchen Liu, Sijun Sun, Quan Zheng, Xiaotian Hu, Zihan Yin, Chengmei Xie, Haiyan Wang, Tianshi Wang, et al.

    Mitochondria harbor the oxidative phosphorylation (OXPHOS) system to sustain cellular respiration. However, the transcriptional regulation of OXPHOS remains largely unexplored. Through the cancer genome atlas (TCGA) transcriptome analysis, transcription factor THAP domain‐containing 3 (THAP3) was found to be strongly associated with OXPHOS gene expression. Mechanistically, THAP3 recruited the histone methyltransferase SET and MYND domain‐containing protein 3 (SMYD3) to upregulate H3K4me3 and promote OXPHOS gene expression. The levels of THAP3 and SMYD3 were altered by metabolic cues. They collaboratively supported liver cancer cell proliferation and colony formation. In clinical human liver cancer, both of them were overexpressed. THAP3 positively correlated with OXPHOS gene expression. Together, THAP3 cooperates with SMYD3 to epigenetically upregulate cellular respiration and liver cancer cell proliferation.


  • Open Access

    SUCLG1 restricts POLRMT succinylation to enhance mitochondrial biogenesis and leukemia progression

    by Weiwei Yan, Chengmei Xie, Sijun Sun, Quan Zheng, Jingyi Wang, Zihao Wang, Cheuk-Him Man, Haiyan Wang, Yunfan Yang, Tianshi Wang, et al.

    Mitochondria are cellular powerhouses that generate energy through the electron transport chain (ETC). The mitochondrial genome (mtDNA) encodes essential ETC proteins in a compartmentalized manner, however, the mechanism underlying metabolic regulation of mtDNA function remains unknown. Here, we report that expression of tricarboxylic acid cycle enzyme succinate-CoA ligase SUCLG1 strongly correlates with ETC genes across various TCGA cancer transcriptomes. Mechanistically, SUCLG1 restricts succinyl-CoA levels to suppress the succinylation of mitochondrial RNA polymerase (POLRMT). Lysine 622 succinylation disrupts the interaction of POLRMT with mtDNA and mitochondrial transcription factors. SUCLG1-mediated POLRMT hyposuccinylation maintains mtDNA transcription, mitochondrial biogenesis, and leukemia cell proliferation. Specifically, leukemia-promoting FMS-like tyrosine kinase 3 ( FLT3 ) mutations modulate nuclear transcription and upregulate SUCLG1 expression to reduce succinyl-CoA and POLRMT succinylation, resulting in enhanced mitobiogenesis. In line, genetic depletion of POLRMT or SUCLG1 significantly delays disease progression in mouse and humanized leukemia models. Importantly, succinyl-CoA level and POLRMT succinylation are downregulated in FLT3- mutated clinical leukemia samples, linking enhanced mitobiogenesis to cancer progression. Together, SUCLG1 connects succinyl-CoA with POLRMT succinylation to modulate mitochondrial function and cancer development.


  • Single‐Site Osmium Catalysts on MgO: Reactivity and Catalysis of CO Oxidation

    by Dong Yang, Shengjie Zhang, Pinghong Xu, Nigel D. Browning, David A. Dixon, Bruce C. Gates

    MgO‐supported osmium dioxo species, described as Os(=O)2{−Osupport}1 or 2 (the brackets denote O atoms of the MgO surface), formed from Os3(CO)12 via supported Os(CO)2, and characterized by spectroscopy, microscopy, and theory, react with ethylene at 298 K to form osmium glycol species or with CO to give osmium mono‐ and di‐carbonyls. Os(=O)2{−Osupport}1 or 2 is the precursor of a CO oxidation catalyst characterized by a turnover frequency of 4.0×10−3 (molecules of CO)/(Os atom×s) at 473 K; the active species are inferred to be osmium monocarbonyls. The structures and frequencies calculated at the level of density functional theory with the B3LYP functional bolster the experimental results and facilitate structural assignments. The lowest‐energy structures have various osmium oxidation and spin states. The results demonstrate not only new chemistry of the supported single‐site catalysts but also their complexity and the value of complementary techniques used in concert to unravel the chemistry.